10.07.2014 • NewsBiesterfeldCarsten HarmsBirger Kuck

Biesterfeld expands its Executive Board

Biesterfeld AG expands its Executive Board from two to four members: beside Birger Kuck, CEO, and Christian Wolfsohn, CFO, Thomas Arnold, Managing Director of Biesterfeld Spezialchemie, and Carsten Harms, Managing Director of Biesterfeld Plastic, join the Executive Board, with immediate effect.
"With this decision the Supervisory Board emphasizes the importance of the operative businesses within the Group and in the Executive Board. We want to give the plastic and the chemicals activities an own voice in the executive board of Biesterfeld AG", explains Dirk Biesterfeld, chairman of the Supervisory Board. Arnold and Harms assume their function in the Executive Board with immediate effect while continuing in their resp. position as Managing Directors within the Biesterfeld Group.

Arnold (54) joined Biesterfeld in May 2013 as Managing Director of Biesterfeld Spezialchemie. Prior to this he held management positions in various renowned, international companies in the trade. Harms (48) has been with Biesterfeld since his trainee. He has driven the development of Biesterfeld Plastic as a one of the leading European distributors for plastics and rubber forward, since 2007 in the position as managing director of Biesterfeld Plastic.

Company

Logo:

Biesterfeld AG

Ferdinandstraße 41
20095 Hamburg
Germany

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read